CDR Hires Former Enovis CEO Matt Trerotola as Operating Advisor

Clayton, Dubilier & Rice has appointed Matt Trerotola, the former CEO of medical technology company Enovis, as an operating advisor — a move that signals the New York-based private equity firm's continued emphasis on hands-on portfolio company transformation over purely financial engineering.

Trerotola spent over three decades at Colfax Corporation and its successor entities, most recently leading Enovis through its 2022 separation from Colfax as an independent publicly traded medical technology business. He'll now work directly with CD&R portfolio companies on operational improvements, strategic repositioning, and M&A integration — the kind of unglamorous, high-impact work that private equity firms increasingly staff with former operators rather than consultants.

The hire comes as CD&R manages a portfolio concentrated in industrial, business services, and healthcare assets — sectors where execution matters as much as deal structure. With $80 billion in assets under management and a roster that includes Belron, Sedgwick, and USI Insurance Services, CD&R has long positioned itself as an operationally intensive firm. Adding a CEO who oversaw complex corporate carve-outs and international growth initiatives fits that model precisely.

What makes this noteworthy isn't just Trerotola's resume. It's what his career reveals about what CD&R values: leaders who've done the messy work of splitting businesses, integrating acquisitions, and driving margin improvement across geographies. Enovis wasn't a startup success story. It was a spin-off that had to build standalone infrastructure, redefine its identity, and execute a portfolio optimization strategy under public market scrutiny. That's the experience CD&R wants in the room when portfolio company CEOs face similar challenges.

Private equity's operating advisor model has evolved sharply over the past decade. Where firms once relied on Big Four consultants or homegrown operations teams, they're now staffing advisory rosters with recently retired public company executives who bring sector credibility and crisis management experience.

Trerotola checks every box on CD&R's likely wish list. He ran a global business with manufacturing footprints across multiple continents. He navigated supply chain disruptions, regulatory complexity in medical devices, and the capital allocation pressures of a newly independent public company. He executed bolt-on M&A to fill portfolio gaps. And he did all of this while reporting to public shareholders and analysts who don't accept "we're building for the long term" as an excuse for missed quarters.

That last point matters more than it seems. Private equity-backed companies operate with longer time horizons than public firms, but they still face quarterly operational reviews, board scrutiny, and the pressure to hit value creation milestones ahead of exit. A CEO who's managed Wall Street expectations can translate that skill to managing PE sponsor expectations — and help portfolio company leaders do the same.

The trend isn't unique to CD&R. Apollo, Blackstone, and Thoma Bravo have all built formal operating partner networks stocked with former Fortune 500 executives. What differentiates firms is how they deploy these advisors: some use them as dealflow sources or brand validators, others embed them in portfolio companies for months at a time. CD&R's approach leans operational — advisors are expected to roll up their sleeves on integration planning, margin improvement programs, and commercial strategy, not just show up for board meetings.

To understand what Trerotola brings to CD&R, you have to understand what Enovis was — and what it wasn't. When Colfax split into two companies in April 2022, Enovis inherited the medical technology and orthopedic device businesses, while Colfax retained the fabrication technology and industrial platform assets. Trerotola became CEO of Enovis, a company that didn't exist as a standalone entity six months earlier.

Spin-offs are brutal. The newly independent company has to stand up IT systems, treasury functions, legal departments, and investor relations infrastructure — often while the parent company is racing to complete the separation and move on. Enovis had to do all of that while maintaining commercial momentum in a competitive medical device market and integrating prior acquisitions that Colfax had made but hadn't fully absorbed.

Trerotola's team also executed a portfolio optimization strategy, divesting non-core assets and doubling down on the Prevention & Recovery and Reconstructive segments. By the time he stepped down in 2024, Enovis had established itself as a credible independent operator with $1.7 billion in annual revenue and a focused product portfolio. That's the kind of transformation narrative CD&R wants replicated across its portfolio: cleaner business models, stronger operational fundamentals, and a clear equity story for the next buyer.

Before Enovis, Trerotola held leadership roles across Colfax's global operations, including President of ESAB (the company's welding and cutting equipment business) and various general management positions. That's three decades of pattern recognition around what works — and what doesn't — when integrating acquisitions, entering new markets, and scaling manufacturing operations.

CD&R didn't hire Trerotola to show up at annual meetings and shake hands. Based on his background, the most immediate use cases are likely post-merger integration planning, commercial excellence programs, and international expansion strategy — particularly in healthcare and industrial portfolio companies where CD&R sees consolidation opportunities.

Operating advisor appointments are forward-looking signals. Firms don't bring on advisors for skills they needed two years ago — they hire for the challenges they see coming in the next 18-24 months across the portfolio.

Trerotola's expertise clusters around a few themes that map directly to CD&R's active investment areas: healthcare services and medical technology, industrial businesses with international footprints, and companies navigating corporate carve-outs or separations. CD&R's current portfolio includes several assets that fit at least one of those categories.

The firm's healthcare holdings have expanded significantly in recent years. It acquired Onex's stake in Clarivate's life sciences and healthcare businesses in 2023, and it continues to pursue add-on acquisitions in healthcare services through existing platforms. Trerotola's medical device background and understanding of regulatory pathways give him immediate relevance there.

But his industrial operations experience might be even more valuable. CD&R has a long history in business services and industrial platforms — sectors where operational leverage and margin improvement drive returns more than revenue growth. Companies like Belron (the global vehicle glass repair business) and Wex (fleet management and payments) require the kind of multi-site operational excellence and supply chain optimization that Trerotola spent decades executing at Colfax.

There's also a subtler implication: CD&R might be positioning for more corporate carve-out opportunities. Public company divestitures have accelerated as conglomerates simplify their portfolios and activist investors push for separations. Buying a business unit from a Fortune 500 parent requires different skills than buying a founder-owned company — you're inheriting shared services, stranded costs, and transition service agreements that expire on tight timelines. Trerotola has lived that movie. If CD&R is underwriting more carve-out deals, having an advisor who's been the CEO on the other side of the transaction is invaluable.

Here's what the press release doesn't say but matters: is Trerotola expected to help CD&R source deals, or just improve the ones they've already made? Operating advisors increasingly play dual roles — they add value post-acquisition, but they're also dealflow generators who spot opportunities in their former industries and make introductions that lead to proprietary transactions.

Given Trerotola's network in medical technology and industrial markets, it's likely CD&R sees him as both. He'll advise existing portfolio companies, but he'll also be a phone call when CD&R is evaluating a bolt-on acquisition in orthopedics or a carve-out in precision manufacturing. That dual mandate is how top-tier operating advisors justify their retainers — they don't just make existing assets better; they help firms deploy capital faster into higher-quality opportunities.

For all the press releases announcing operating advisor appointments, there's surprisingly little transparency around what these roles entail day-to-day. The reality varies wildly by firm — some advisors are full-time equivalents embedded in a single portfolio company for 12-18 months, others are part-time coaches who join quarterly business reviews and weigh in on strategic decisions.

CD&R's model tends toward the hands-on end of the spectrum. The firm has a formal operating group led by partners who've held CEO and COO roles at portfolio companies. Advisors like Trerotola slot into that structure, working closely with deal teams and portfolio company management on specific value creation initiatives: pricing optimization, sales force effectiveness, cost structure redesign, M&A integration.

The best operating advisors don't try to run the company — they've already been the CEO, and they're not interested in doing it again. What they provide is pattern recognition and air cover. A portfolio company CEO facing a tough margin improvement decision or a controversial restructuring can pressure-test their plan with someone who's made similar calls and lived with the consequences. That's worth more than a consulting deck.

There's also a less obvious function: operating advisors help PE firms avoid the "financialization" trap. When deal teams push portfolio companies too hard on short-term EBITDA growth, operating advisors are often the ones who push back and say "this will break the business." They've seen what happens when you cut R&D too deep or defer maintenance too long. That institutional memory is a check on deal model assumptions that don't survive contact with reality.

Operating advisors aren't typically paid like full-time executives, but they're not cheap either. Compensation structures vary: some get annual retainers in the low seven figures, others get per-project fees or success-based payments tied to portfolio company value creation. Many receive carry allocations in the funds they support, aligning their incentives with long-term fund performance rather than just advisory fees.

For someone like Trerotola — a recently retired public company CEO with board opportunities and speaking circuit options — the appeal isn't purely financial. Operating advisors often describe the role as intellectually engaging without the operational grind of running a company. You get to solve problems without dealing with HR issues, earnings calls, or compliance minutiae. For former CEOs who still want to build things but don't want to run them, it's an ideal next chapter.

The market for operating advisors has gotten competitive. As more PE firms build operating platforms, they're all fishing from the same talent pool: recently retired Fortune 500 CEOs and division presidents who still have energy and credibility but don't want another 60-hour-week job. That's a small group, and the best ones have options.

What makes someone attractive to a firm like CD&R? It's not just resume — it's cultural fit and relevance to the portfolio. Trerotola's background in industrial operations and medical devices maps directly to CD&R's investment focus. He's worked in private equity-owned environments (Colfax had multiple PE ownership chapters before going public). He's led businesses through economic cycles, regulatory scrutiny, and competitive disruption. And critically, he's seen both sides of the PE relationship — he's managed businesses backed by sponsors, and he's worked with sponsors on exit processes.

That last point is underrated. Operating advisors who've only worked in public companies sometimes struggle to adapt to the pace and governance model of PE-backed businesses. Trerotola won't have that learning curve — he's already fluent in the language sponsors speak and the priorities they care about.

If you're a CEO at a CD&R portfolio company in healthcare or industrials, there's a decent chance you'll get an email in the coming months introducing you to Trerotola and suggesting a call. That's typically how these engagements start — informal, low-pressure, framed as "let's see if there's a fit" rather than "corporate has decided you need help."

The smart CEOs treat those calls as opportunities, not audits. Operating advisors can be invaluable thought partners — but only if the portfolio company CEO is willing to be candid about where the business is struggling and open to outside perspectives. The worst outcome is treating the advisor like a compliance exercise: take the call, nod politely, then ignore the advice. That wastes everyone's time and signals to the sponsor that the CEO isn't coachable.

The areas where Trerotola will likely have the most immediate impact are post-acquisition integration, international expansion strategy, and operational efficiency programs. Those are the initiatives where pattern recognition matters most — where having seen the movie before lets you avoid predictable mistakes and accelerate value capture.

For CD&R, the ROI on an operating advisor isn't measured in hours billed. It's measured in whether portfolio companies hit their value creation plans faster, whether bolt-on acquisitions integrate cleanly, and whether exits happen at higher multiples because the businesses are operationally tighter and strategically clearer. If Trerotola helps CD&R add 50-100 basis points to exit multiples across even a handful of deals, the appointment more than pays for itself.

Every operating advisor hire comes with an implicit promise: this person will make our portfolio companies better. But "better" is vague, and the metrics that matter vary by portfolio. Will CD&R measure Trerotola's impact on EBITDA margin improvement? Revenue growth? Integration speed? Exit multiple expansion? The firms that get the most value from operating advisors are the ones that define success upfront and track it rigorously.

There's also the cultural integration question. Operating advisors are most effective when they're genuinely integrated into the firm's operating model — when deal teams know to call them early in due diligence, when portfolio company CEOs see them as allies rather than overseers, when their insights actually change decisions. That requires intentional relationship-building, not just an announcement and a business card.

CD&R has a strong track record of operationally intensive value creation, which suggests they'll deploy Trerotola thoughtfully. But the proof will be in whether portfolio companies two years from now point to specific decisions or initiatives where his input made a material difference. Operating advisors are easy to hire. Making them genuinely useful is harder.

What's clear is that CD&R is doubling down on operational depth as a competitive advantage. In a market where dry powder is abundant and assets are expensive, the firms that win are the ones that create value after the deal closes — through better operations, smarter M&A, and faster execution. Hiring someone who's built and spun off billion-dollar businesses is a signal that CD&R intends to compete on those dimensions, not just on access to capital.

Step back from the specifics of this hire, and the bigger story is how private equity's operating model continues to professionalize. Twenty years ago, most PE firms were financially engineered: they bought companies, levered them up, cut costs, and sold. Today's top-quartile firms look more like strategic holding companies, with in-house operating teams, sector-specific experts, and formal value creation playbooks.

That shift has implications for every stakeholder. Portfolio company CEOs need to be comfortable with higher levels of sponsor involvement — not micromanagement, but genuine strategic partnership. Limited partners should be evaluating GPs on the strength of their operating platforms, not just their deal track records. And executives considering PE careers should be thinking about the operating advisor path as a legitimate post-CEO chapter, not just a side gig.

Trerotola's appointment is one data point in a larger trend: the best private equity firms are building institutional capabilities around operational value creation, and they're staffing those capabilities with people who've actually run businesses at scale. CD&R has been ahead of that curve for years. Bringing Trerotola into the fold keeps them there.

The question for CD&R's competitors isn't whether they should build similar capabilities — it's whether they can attract talent of the same caliber. Operating advisors have options, and they gravitate toward firms with strong portfolios, clear value creation frameworks, and cultures that genuinely listen to operating perspectives. CD&R checks all those boxes. That's why this hire was possible, and it's why it matters.